Vanda Pharmaceuticals Shares HETLIOZ® FDA Review Progress

Vanda Pharmaceuticals Inc. (VNDA) has released an update.

Vanda Pharmaceuticals Inc. announced an update on the FDA’s review of their application for HETLIOZ® to treat insomnia, sharing the progress in a press release. This latest development could be a significant step for the company and is of interest to investors monitoring Vanda’s market movements.

For further insights into VNDA stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.